- Home
- LCFY vs RNAZ Comparison
LCFY vs RNAZ Comparison
Compare LCFY & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCFY
- RNAZ
- Stock Information
- Founded
- LCFY 2009
- RNAZ 2016
- Country
- LCFY Australia
- RNAZ United States
- Employees
- LCFY N/A
- RNAZ N/A
- Industry
- LCFY
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- LCFY
- RNAZ Health Care
- Exchange
- LCFY Nasdaq
- RNAZ Nasdaq
- Market Cap
- LCFY 9.2M
- RNAZ 8.7M
- IPO Year
- LCFY 2022
- RNAZ 2021
- Fundamental
- Price
- LCFY $4.88
- RNAZ $12.69
- Analyst Decision
- LCFY
- RNAZ Strong Buy
- Analyst Count
- LCFY 0
- RNAZ 1
- Target Price
- LCFY N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- LCFY 63.3K
- RNAZ 421.6K
- Earning Date
- LCFY 10-10-2025
- RNAZ 11-13-2025
- Dividend Yield
- LCFY N/A
- RNAZ N/A
- EPS Growth
- LCFY N/A
- RNAZ N/A
- EPS
- LCFY N/A
- RNAZ N/A
- Revenue
- LCFY $2,231,313.00
- RNAZ N/A
- Revenue This Year
- LCFY N/A
- RNAZ N/A
- Revenue Next Year
- LCFY N/A
- RNAZ N/A
- P/E Ratio
- LCFY N/A
- RNAZ N/A
- Revenue Growth
- LCFY N/A
- RNAZ N/A
- 52 Week Low
- LCFY $2.51
- RNAZ $6.15
- 52 Week High
- LCFY $13.98
- RNAZ $568.26
- Technical
- Relative Strength Index (RSI)
- LCFY 37.77
- RNAZ 48.74
- Support Level
- LCFY $4.73
- RNAZ $12.11
- Resistance Level
- LCFY $5.50
- RNAZ $13.92
- Average True Range (ATR)
- LCFY 0.30
- RNAZ 1.26
- MACD
- LCFY -0.08
- RNAZ -0.24
- Stochastic Oscillator
- LCFY 15.32
- RNAZ 15.14
About LCFY Locafy Limited
Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.